ERCC6 and pancreatic neoplasm: Although the above study did not use pancreatic cancer cell, considering the inclusion of 5-fluorouracil in FOLFIRINOX regimen, it is likely that 5-fluorouracil in addition to oxaliplatin may have influenced the difference in response to FOLFIRINOX according to the ERCC6 variant.